Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.

Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA.

Cancer Immunol Res. 2019 Jun 11. doi: 10.1158/2326-6066.CIR-18-0874. [Epub ahead of print]

PMID:
31186248
2.

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.

Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG.

J Immunother Cancer. 2019 Feb 8;7(1):37. doi: 10.1186/s40425-019-0518-z.

3.

Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.

Rosato RR, Dávila-González D, Choi DS, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC.

Breast Cancer Res. 2018 Sep 5;20(1):108. doi: 10.1186/s13058-018-1037-4.

4.

Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.

Lin S, Huang G, Cheng L, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X, Li P.

MAbs. 2018 Nov-Dec;10(8):1301-1311. doi: 10.1080/19420862.2018.1518948. Epub 2018 Oct 2.

PMID:
30204048
5.

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.

Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG.

FASEB J. 2018 Mar;32(3):1537-1549. doi: 10.1096/fj.201700740R. Epub 2018 Jan 3.

6.

Long-term leukocyte reconstitution in NSG mice transplanted with human cord blood hematopoietic stem and progenitor cells.

Audigé A, Rochat MA, Li D, Ivic S, Fahrny A, Muller CKS, Gers-Huber G, Myburgh R, Bredl S, Schlaepfer E, Scherrer AU, Kuster SP, Speck RF.

BMC Immunol. 2017 May 30;18(1):28. doi: 10.1186/s12865-017-0209-9.

7.

Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.

Pyo KH, Kim JH, Lee JM, Kim SE, Cho JS, Lim SM, Cho BC.

Lung Cancer. 2019 Jan;127:112-121. doi: 10.1016/j.lungcan.2018.11.035. Epub 2018 Nov 27.

PMID:
30642538
8.

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.

Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B.

J Transl Med. 2018 Nov 26;16(1):328. doi: 10.1186/s12967-018-1704-3.

9.

Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice.

Chen BP, Galy A, Kyoizumi S, Namikawa R, Scarborough J, Webb S, Ford B, Cen DZ, Chen SC.

Blood. 1994 Oct 15;84(8):2497-505.

10.

Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.

Kozlowska AK, Kaur K, Topchyan P, Jewett A.

Cancer Immunol Immunother. 2016 Jul;65(7):835-45. doi: 10.1007/s00262-016-1822-9. Epub 2016 Mar 31. Review.

11.

Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.

Morton JJ, Keysar SB, Perrenoud L, Chimed TS, Reisinger J, Jackson B, Le PN, Nieto C, Gomez K, Miller B, Gao D, Somerset H, Wang XJ, Jimeno A.

Mol Carcinog. 2018 Nov;57(11):1651-1663. doi: 10.1002/mc.22887. Epub 2018 Sep 3.

PMID:
30129680
12.

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.

Höchst B, Schildberg FA, Sauerborn P, Gäbel YA, Gevensleben H, Goltz D, Heukamp LC, Türler A, Ballmaier M, Gieseke F, Müller I, Kalff J, Kurts C, Knolle PA, Diehl L.

J Hepatol. 2013 Sep;59(3):528-35. doi: 10.1016/j.jhep.2013.04.033. Epub 2013 May 9.

PMID:
23665041
13.

Ex Vivo Gene Therapy: Graft-versus-host Disease (GVHD) in NSG™ (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) Mice Transplanted with CD34+ Human Hematopoietic Stem Cells.

Chandra S, Cristofori P, Fonck C, O'Neill CA.

Toxicol Pathol. 2019 May 7:192623319844484. doi: 10.1177/0192623319844484. [Epub ahead of print]

PMID:
31064282
14.

CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.

Cullup H, Hsu AK, Kassianos AJ, McDonald K, Radford KJ, Rice AM.

J Immunother. 2011 May;34(4):362-71. doi: 10.1097/CJI.0b013e31821b7230.

PMID:
21499125
15.

Human allogeneic stem cell maintenance and differentiation in a long-term multilineage SCID-hu graft.

Fraser CC, Kaneshima H, Hansteen G, Kilpatrick M, Hoffman R, Chen BP.

Blood. 1995 Sep 1;86(5):1680-93.

16.

Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice.

Hanazawa A, Ito R, Katano I, Kawai K, Goto M, Suemizu H, Kawakami Y, Ito M, Takahashi T.

Front Immunol. 2018 Feb 2;9:152. doi: 10.3389/fimmu.2018.00152. eCollection 2018.

17.
18.

Reconstitution of human lymphocytes following ex vivo expansion of human umbilical cord blood CD34+ cells and transplantation in Rag2-/- gamma c-/- mice model.

Choi BK, Joo SY, Moon C, Park KS, Kim SH, Park JB, Jung GO, Choi GS, Kwon CH, Chun JM, Joh JW, Lee SK, Kim SJ.

Transplant Proc. 2008 Oct;40(8):2655-60. doi: 10.1016/j.transproceed.2008.08.011.

PMID:
18929829
19.

Early severe impairment of hematopoietic stem and progenitor cells from the bone marrow caused by CLP sepsis and endotoxemia in a humanized mice model.

Skirecki T, Kawiak J, Machaj E, Pojda Z, Wasilewska D, Czubak J, Hoser G.

Stem Cell Res Ther. 2015 Aug 14;6:142. doi: 10.1186/s13287-015-0135-9.

20.

An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells.

Rosler ES, Brandt JE, Chute J, Hoffman R.

Blood. 2000 Nov 15;96(10):3414-21.

Supplemental Content

Support Center